Tarsus Pharmaceuticals, Inc. (TARS) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

18/25

Growth 5 Margin 5 Expansion 4 Platform 2 Financial 2

latest quarter score

Earnings Reports

18
Tarsus (TARS) Q2 2026: Extenvi Soars 69% as Retina Pipeline Expands with $450M ALK001 Bet
August 07, 2026
16
TARS Q1 2026: Xtemvi Drives 85% Growth, Pipeline Expands Beyond Core Eye Care
May 07, 2026
16
TARS Q4 2025: Xtemvi Drives 50% Sales Growth, $2B+ U.S. Peak Target Unveiled
February 25, 2026
17
Tarsus (TARS) Q3 2025: 147% Growth Underscores Xdemvi’s Blockbuster Trajectory
November 05, 2025
17
TARS Q2 2025: Xdemvi Prescriber Base Expands 33%, Unlocking New Eye Care Market Depth
August 06, 2025
15
Tarsus (TARS) Q1 2025: Xdemvi Sales Surge 217% as DTC and Medicare Access Unlock Prescriber Shift
July 04, 2025

Browse all companies